Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $11.13 million versus the consensus estimate of $3.52 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.